Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Thermo Fisher Scientific Inc (TMO) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Report Scope:

Thermo Fisher Scientific (TMO): 2024 Product Pipeline Analysis, Ongoing Clinical Trials Insights, and Developments, Including New CXCL10 Testing Service

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Here's Why Thermo Fisher (TMO) Should be in Your Portfolio

Thermo Fisher Scientific is well-positioned to benefit from the demand for innovation in the healthcare and biotech sectors. The company's strategic acquisitions have improved its growth capabilities and deepened its relationships with biopharma partners. Despite a low dividend yield, TMO has a history of strong total returns and consistent dividend growth, making it a compelling long-term investment.

Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends

ROCHESTER, N.Y.--(BUSINESS WIRE)--In advance of the busy summer travel season when an estimated 82% of Americans are planning to travel, EF Go Ahead Tours, a leading provider of guided group tours, proudly names Nalgene Outdoor, the original manufacturer of reusable water bottles as its official sustainable water bottle provider. This reflects a shared commitment to environmental responsibility in reducing single-use plastics in all of life's travel adventures, from the everyday to the once-in-.

Nalgene Outdoor Named EF Go Ahead Tours' Official Water Bottle for Sustainable Travel

ANAHEIM, Calif.--(BUSINESS WIRE)--To help accelerate the promise of precision medicine, Thermo Fisher Scientific today unveiled its new solutions accelerating research workflows at the annual American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, in Anaheim, California. The new mass spectrometry and chromatography instruments and software solutions enable customers to unlock deeper analytical insights with built-for-purpose flexibility, improving produc.

Thermo Fisher Scientific Unveils New Solutions Supporting Research Workflows at ASMS 2024

ANAHEIM, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their translational omics research and make breakthrough discoveries more efficiently. The Stellar MS powers translational research, the conversion of basic science discoveries into clinical application.

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

BLEISWIJK, Netherlands--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced therapies. The new current good manufacturing practice (cGMP) facility in Bleiswijk, Netherlands provides pharma and biopharma customers tailored, end-to-end support throughout the clinical supply chain for high-value therap.

Thermo Fisher Scientific Opens New GMP-certified Ultra-cold Facility in the EU to Accelerate Advanced Therapies Development

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic Regulations (IVDR) 2017/746 in the European Union. These compliance updates will enable cytogenetics testing laboratories to adapt to the latest medical device safety and efficacy frameworks and conformity assessments. “Thermo.

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its 2023 Corporate Social Responsibility (CSR) report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues. “Thermo Fisher is driven by a profound Mission – to enable our customers to make the world healthier, cleaner, and safer,” said Marc N. Casper, chairman, president and chief executive officer.

Thermo Fisher Scientific Releases 2023 Corporate Social Responsibility Report

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Thermo Fisher (TMO) Up 2.3% Since Last Earnings Report: Can It Continue?

Akoya Biosciences Inc

Bionano Genomics

Cytek Biosciences

Danaher

Standard BioTools Inc

908 Devices

Olink Holding AB

Singular Genomics Systems

QIAGEN

Quantum-Si

Revvity Inc

Seer

10X Genomics

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Lab Instrument Industry Update - New Commercial Entrants

Gilead Sciences

Novavax

While it tends to fly under the radar for many people, the biotech industry has seen a resurgence in investor interest over the last couple of years. While there could be several reasons for this, such as the COVID-19 pandemic bringing the value of biotechnology to the forefront or even the expansion of education in the biosciences, the fact remains – biotech is getting more attention than ever before.

3 Biotech Stocks to Buy Now: May 2024

Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.

Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Applied Biosystems™ Axiom™ BloodGenomiX™ Array* and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research. The new array detects most extended and rare blood groups, tissue (HLA) and platelet (HPA) types in a single, high-throughput assay, supporting future advancements in donor blood matching for extended phenotypes. Blood typing is a.

Thermo Fisher Scientific Introduces Array-based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

Thermo Fisher Scientific Inc. (NYSE:TMO ) Bank of America Securities 2024 Health Care Conference Call May 14, 2024 11:00 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin Thanks everyone for joining us. For those of you who don't know me, my name is Mike Ryskin on BofA life science tools and diagnostics team.

Thermo Fisher Scientific Inc. (TMO) Presents at Bank of Bank of America Securities 2024 Health Care Conference (Transcript)

Britain's competition regulator said on Friday it has initiated a probe into U.S. medical equipment maker Thermo Fisher Scientific's $3.1 billion deal to buy Swedish biotech firm Olink Holding AB.

UK's CMA kicks off probe into Thermo Fisher-Olink deal

Deere & Company

Intuitive Surgical

NVIDIA

Rockwell Automation

Teradyne

Tesla

Investors seeking reliable AI-powered returns should consider robotics stocks. Many companies are leveraging artificial intelligence to create human-like robots.

7 Robotics Stocks to Bet On for Reliable AI-Powered Returns

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities Health Care Conference on Tuesday, May 14, 2024 at 11:00 a.m. (ET). The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in s.

Thermo Fisher Scientific to Present at BofA Securities 2024 Health Care Conference on May 14

Review Thermo Fisher's (TMO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Don't Overlook Thermo Fisher (TMO) International Revenue Trends While Assessing the Stock

WEST HILLS, Calif.--(BUSINESS WIRE)--For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of rejection, both of which may carry complications. Now, a simple, urine-based assay that detects the CXCL10 chemokine may make care more convenient and less invasive for the nearly 250,000 Americans living with a kidney transplant. Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers,.

Thermo Fisher Scientific Launches New CXCL10 Testing Service

Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.

Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up

Thermo Fisher Scientific Inc. (NYSE:TMO ) Q1 2024 Earnings Call Transcript April 24, 2024 8:30 AM ET Company Participants Rafael Tejada - VP, IR Marc Casper - Chairman, President and CEO Stephen Williamson - SVP and CFO Conference Call Participants Doug Schenkel - Wolfe Research Mike Ryskin - Bank of America Jack Meehan - Nephron Research Rachel Vatnsdal - JPMorgan Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Luke Sergott - Barclays Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2024 First Quarter Conference Call. My name is Angela, and I'll be coordinating your call today.

Thermo Fisher Scientific Inc. (TMO) Q1 2024 Earnings Call Transcript

Boeing

Boeing posted a slimmer loss per share while Thermo Fisher outperformed. Durable Goods performed as expected.

Boeing Mixed in Q1, TMO Beats; Durable Goods In-Line

Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Thermo Fisher (TMO) Q1 Earnings: A Look at Key Metrics

Thermo Fisher on Wednesday beat Wall Street estimates for quarterly profit and raised its annual profit forecast, betting on improved demand for its products and services used in drug development and sending shares up about 4% premarket.

News for Thermo Fisher Scientific Stock (TMO)